同步放化疗对食管癌患者生存率及血清TSP-1 microRNA-21水平的影响

Effect of Concurrent Radiotherapy and Chemotherapy on Survival Rate andSerum TSP-1 and MicroRNA-21 Levels in Patients with Esophageal Cancer

目的:研究同步放化疗对食管癌患者生存率及血清TSP-1、microRNA-21水平的影响。方法:选取2015年2月至2017年1月的110例食管癌患者。按照简单随机分组法分为观察组(n=59)和对照组(n=51),对照组采用序贯化放疗法治疗,观察组采用同步放化疗治疗。观察两组总缓解率、1年及2年生存率,血清凝血酶敏感蛋白-1(TSP-1)、微小RNA-21(microRNA-21)水平、卡氏(KPS)评分、不良反应情况。结果:治疗后,观察组总缓解率显著高于对照组[88.14%(52/59)vs66.67%(34/51)](P<0.05);两组1年生存率无显著差异(P>0.05),观察组2年生存率显著高于对照组[71.19%(42/59)vs33.3%(17/51)](P<0.05);血清TSP-1、microRNA-21水平均显著高于对照组[(189.63±9.20)ng/mL vs(145.86±7.49)ng/mL,(6.96±1.05)-log vs(12.82±2.04)-log](P<0.05);KPS评分显著高于对照组[(75.38±3.59)ng/mL vs(64.92±3.05)ng/mL](P<0.05);两组不良反应发生率均无统计学意义(P>0.05)。结论:同步放化疗对食管癌的临床治疗显著,可有效改善患者的临床症状,提高患者生存率,抑制肿瘤复发、转移,促进患者预后。

Objective:To study the effect of concurrent radiotherapy and chemotherapy on survival rate and serum TSP-1 and microRNA-21 levels in patients with esophageal cancer.Methods:110 esophageal cancer patients who received therapy from February 2015 to January 2017 in our hospital were selected as research objects.According to simple random grouping method,those patients were divided into the observation group(n=59)and the control group(n=51).The control group was treated with sequential chemoradiotherapy,while the observation group was treated with concurrent radiotherapy and chemotherapy.Post-treatment comparison between both groups was made in the total remission rate,1-year and 2-year survival rate,serum TSP-1,microRNA-21 level,Karnofsky(KPS)score,and adverse reactions.Results:After treatment,the total remission rate of the observation group was significantly higher than that of the control group[88.14%(52/59)vs66.67%(34/51)](P<0.05).There was no significant difference in 1-year survival rate between the two groups(P>0.05).The 2-year survival rate of the observation group was significantly higher than that of the control group[71.19%(42/59)vs33.3%(17/51)](P<0.05).Serum Thrombin sensitive protein-1(TSP-1)and microRNA-21 levels were significantly higher than those in the control group[(189.63±9.20)ng/mL vs(145.86±7.49)ng/mL,(6.96±1.05)-log vs(12.82±2.04)-log](P<0.05).KPS score was significantly higher than that of the control group[(75.38±3.59)ng/mL vs(64.92±3.05)ng/mL](P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Synchronous radiotherapy and chemotherapy can effectively improve the clinical symptoms,improve the survival rate of patients,inhibit tumor recurrence and metastasis,and promote the prognosis of patients.